Skip to main content
ChenDermatologist
ChenDermatologist
Dr. Chen Yi-Jia · Dermatology Notes
English version. Prefer Traditional Chinese? Switch to Chinese
Patient education · AD / Topical Per AAD 2023 + UpToDate 2024 Content updated 2026-10-16 · Physician reviewed 2026-05-09

Topical therapy for atopic dermatitis
Moisturizers, steroids, TCI, PDE4, topical JAKi compared

TL;DR:Daily moisturising is the foundation — enough of it (250-500 g a week for an adult), with the base mattering more than the brand. Flares take an appropriately potent steroid for 7-14 days, then proactive twice-weekly maintenance, with non-steroidal options such as TCI for the face and folds.

80% of atopic dermatitis is controlled with topical therapy. Three pillars: (1) Daily moisturizer ≥ 250 g/week, soak-and-seal within 3 minutes after bathing; (2) Topical corticosteroids for acute flares (potency 1-7 by site); (3) TCI or newer non-steroid topicals for face, folds, long-term maintenance. Newer agents post-2017: crisaborole 2% (PDE4 inhibitor), ruxolitinib 1.5% cream (topical JAK 1/2 inhibitor), tapinarof, roflumilast.

Cover and reading information
In this article
  1. Foundation 1: Daily moisturizer
  2. Foundation 2: Topical corticosteroids
  3. Topical calcineurin inhibitors (TCI)
  4. Newer non-steroid topicals (since late 2016)
  5. Wet wrap therapy
  6. Bathing & bleach baths
  7. Practical treatment ladder
  8. Bottom line
Key Fact (Sidbury 2023, JAAD topical · UpToDate 2024)

Moisturizer is the lifelong cornerstone of AD care — not just during acute flares, but Daily. AAD 2023 strongly recommends using ≥ 250 g of moisturizer per week, which reduces acute flare frequency by about 30–50%."Soak and seal" principle: shower ≤ 10 min + lukewarm water + no soap scrubbing + apply moisturizer + topical medication within 3 min of toweling — works best. Newer non-steroidal topicals (PDE4i, topical JAKi, tapinarof, roflumilast) help with special sites, long-term maintenance, and reduce steroid use possible.

Foundation 1: Daily moisturizer

AAD 2023 adult topical-therapy guideline, strong recommendation: ≥ 250 g/week, soak-and-seal (10-minute lukewarm bath, syndet not soap, then moisturizer within 3 minutes). Ointments > creams > lotions. Early small trials (e.g., Simpson 2014) found that daily emollients from birth reduced AD incidence by about 50%, but large 2020 randomized trials (BEEP, PreventADALL) and a 2022 Cochrane review did not confirm that routine emollients prevent AD in healthy infants, and they may increase skin infections. The AAD 2026 pediatric AD prevention guideline gives a conditional recommendation (low certainty of evidence) only for children at risk for AD: regular moisturizing skin care before age 2 may reduce the risk of developing AD; for the general population, it states that the evidence does not support a protective benefit. Whether your baby is at high risk and should be moisturized regularly from early on is worth discussing with your doctor; the most certain value of moisturizers is in treating and maintaining established AD.

Foundation 2: Topical corticosteroids

Class 1-7 by potency. Use appropriate-strength TCS BID for 7-14 days during flares, then proactive maintenance (twice weekly). FTU dosing: 1 FTU = 0.5 g covers 2 adult palms. Avoid steroidophobia — adequate short-term TCS plus proactive maintenance results in less cumulative steroid exposure than under-treatment with repeat flares.

Topical calcineurin inhibitors (TCI)

Tacrolimus 0.03–0.1% ointment, pimecrolimus 1% cream. Best for face, eyelids, intertriginous; long-term proactive maintenance. Initial burning/stinging usually resolves; chill the tube, pre-apply moisturizer. FDA black-box warning not supported by long-term registry data.

Newer non-steroid topicals (since late 2016)

  • Crisaborole 2% ointment (Eucrisa) — PDE4 inhibitor; BID; mild-moderate AD; ≥ 3 months age.
  • Ruxolitinib 1.5% cream (Opzelura) — topical JAK1/2 inhibitor; BID × 8 weeks; EASI-75 ~53%, IGA 0/1 ~50% — comparable to mid-potency steroid; FDA-approved, extended to ages 2-11 in 2025. In Taiwan, topical ruxolitinib (approved 2026) is licensed only for non-segmental facial vitiligo in patients ≥ 12, not for AD.
  • Tapinarof 1% cream (Vtama) — AhR modulator; QD; FDA-approved 2024 for AD (age ≥ 2); AAD 2025 strong recommendation; not available in Taiwan.
  • Roflumilast 0.15% cream (Zoryve) — strong PDE4 inhibitor; QD; FDA-approved 2024 for AD (0.15%, age ≥ 6) and 2025 (0.05%, ages 2-5); AAD 2025 strong recommendation; topical form not available in Taiwan.

Wet wrap therapy

For severe acute flares (especially children): bath, apply low-mid TCS + emollient, wet inner cotton layer, dry outer cotton layer, wear 2-12 hours. 3-7 days reduces EASI dramatically.

Bathing & bleach baths

Daily ≤ 10 min lukewarm baths, syndet cleansers (pH 5.5, no SLS). Dilute bleach bath (¼–½ cup of 6% bleach in a tub, ≈ 0.005% NaOCl) twice weekly reduces Staphylococcus aureus colonization (conditional recommendation in the AAD 2026 pediatric AD guideline; the AAD 2023 adult topical guideline conditionally recommends against topical antiseptics, noting only that bleach baths may be suggested to reduce severity in moderate-to-severe AD with signs of secondary bacterial infection).

Practical treatment ladder

Daily moisturizer always. Mild flare: low-mid TCS or TCI 7-14d. Moderate: mid-potent TCS + adjunct (ruxolitinib/crisaborole). Severe: potent TCS + wet wrap + bleach bath + consider systemic. Maintenance: TCI/PDE4i/topical JAK twice-weekly proactive.

Bottom line

"Daily moisturizer + adequate TCS during flares + proactive maintenance with non-steroid topicals" is the modern foundation. Step up to systemic therapy if 4-8 weeks of consistent topical care fails.